MS608PABX

antibody from Invitrogen Antibodies

Targeting: TIMP1 CLGI, EPO, TIMP

Provider product page for MS608PABX

Western blot

Antibody data

Antibody Data
Antigen structure
References [39]
Comments [0]
Validations
Immunocytochemistry [1]
Immunohistochemistry [1]
Flow cytometry [1]
Other assay [2]

Submit

Product number: MS608PABX - Provider product page
Provider: Invitrogen Antibodies
Product name: TIMP1 Monoclonal Antibody (102D1)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MS608PABX targets TIMP-1 in immunohistochemistry and western blot applications and shows reactivity with human samples. The MS608PABX immunogen is recombinant human TIMP-1. MS608PABX detects TIMP-1 which has a predicted molecular weight of approximately 21 kDa.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: 102D1
Vial size: 200 µg
Concentration: 1 mg/mL
Storage: -20°C

TIMP1 protein structure - MS608PABX shown in red.

Submitted references Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.

Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, D'Anca M, Pellegrino E, Piva R, Inghirami G, Capelli C, Introna M, Baldini L, Chiaramonte R, Lombardi L, Neri A
Genes, chromosomes & cancer 2014 Feb;53(2):154-67

Correlation of bacterial coinfection versus matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 expression in aortic aneurysm and atherosclerosis.

Roggério A, Sambiase NV, Palomino SA, de Castro MA, da Silva ES, Stolf NG, de Lourdes Higuchi M
Annals of vascular surgery 2013 Oct;27(7):964-71

Immunoexpression of matrix metalloproteinases and their inhibitors in different areas of oral squamous cell carcinoma.

Suarez-Roa ML, Asbun-Bojalil J, Ruiz-Godoy LM, Meneses-García AA
Australian dental journal 2012 Sep;57(3):300-7

Comparative study of the immunohistochemical expression of tissue inhibitors of metalloproteinases 1 and 2 between clearly invasive carcinomas and "in situ" trophoblast invasion.

Dimo B, Ioannidis I, Karameris A, Vilaras G, Tzoumakari P, Nonni A, Patsouris E, Lazaris AC
Medical oncology (Northwood, London, England) 2012 Sep;29(3):2270-5

Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events.

González LO, González-Reyes S, Junquera S, Marín L, González L, Del Casar JM, González JM, Vizoso F
Journal of cancer research and clinical oncology 2010 Sep;136(9):1313-21

Study of matrix metalloproteinases and their inhibitors in prostate cancer.

Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ
British journal of cancer 2010 Mar 2;102(5):922-9

Expression of metalloproteases and their inhibitors in different histological types of breast cancer.

Del Casar JM, González-Reyes S, González LO, González JM, Junquera S, Bongera M, García MF, Andicoechea A, Serra C, Vizoso FJ
Journal of cancer research and clinical oncology 2010 Jun;136(6):811-9

Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast.

Gonzalez LO, Junquera S, del Casar JM, González L, Marín L, González-Reyes S, Andicoechea A, González-Fernández R, González JM, Pérez-Fernández R, Vizoso FJ
Human pathology 2010 Jul;41(7):980-9

Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.

del Casar JM, Carreño G, González LO, Junquera S, González-Reyes S, González JM, Bongera M, Merino AM, Vizoso FJ
Journal of cancer research and clinical oncology 2010 Jul;136(7):1049-58

Hypoxia promotes metastasis in human gastric cancer by up-regulating the 67-kDa laminin receptor.

Liu L, Sun L, Zhao P, Yao L, Jin H, Liang S, Wang Y, Zhang D, Pang Y, Shi Y, Chai N, Zhang H, Zhang H
Cancer science 2010 Jul;101(7):1653-60

Immunohistochemical expression of matrix metalloproteinases in photodamaged skin by photodynamic therapy.

Almeida Issa MC, Piñeiro-Maceira J, Farias RE, Pureza M, Raggio Luiz R, Manela-Azulay M
The British journal of dermatology 2009 Sep;161(3):647-53

Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma.

Altadill A, Rodríguez M, González LO, Junquera S, Corte MD, González-Dieguez ML, Linares A, Barbón E, Fresno-Forcelledo M, Rodrigo L, Vizoso FJ
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2009 Oct;41(10):740-8

Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas.

Del Casar JM, González LO, Alvarez E, Junquera S, Marín L, González L, Bongera M, Vázquez J, Vizoso FJ
Breast cancer research and treatment 2009 Jul;116(1):39-52

Menstrual activity of matrix metalloproteinases is decreased in endometrium regenerating after thermal ablation.

Brun JL, Galant C, Delvaux D, Lemoine P, Henriet P, Courtoy PJ, Marbaix E
Human reproduction (Oxford, England) 2009 Feb;24(2):333-40

The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions.

Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellanno M, Bassilian S, Bedi GS, Boontheung P, Cociorva D, Delahunty CM, Denny T, Dunsmore J, Faull KF, Gilligan J, Gonzalez-Begne M, Halgand F, Hall SC, Han X, Henson B, Hewel J, Hu S, Jeffrey S, Jiang J, Loo JA, Ogorzalek Loo RR, Malamud D, Melvin JE, Miroshnychenko O, Navazesh M, Niles R, Park SK, Prakobphol A, Ramachandran P, Richert M, Robinson S, Sondej M, Souda P, Sullivan MA, Takashima J, Than S, Wang J, Whitelegge JP, Witkowska HE, Wolinsky L, Xie Y, Xu T, Yu W, Ytterberg J, Wong DT, Yates JR 3rd, Fisher SJ
Journal of proteome research 2008 May;7(5):1994-2006

Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.

Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, Rodriguez JC, Lamelas ML, Vizoso FJ
BMC cancer 2008 May 28;8:149

A mouse to human search for plasma proteome changes associated with pancreatic tumor development.

Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM
PLoS medicine 2008 Jun 10;5(6):e123

Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.

Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A
American journal of clinical oncology 2008 Feb;31(1):55-63

Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.

Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Daraï E
International journal of oncology 2008 Dec;33(6):1239-46

Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse.

González LO, Pidal I, Junquera S, Corte MD, Vázquez J, Rodríguez JC, Lamelas ML, Merino AM, García-Muñiz JL, Vizoso FJ
British journal of cancer 2007 Oct 8;97(7):957-63

Multinucleate giant cells release functionally unopposed matrix metalloproteinase-9 in vitro and in vivo.

Zhu XW, Price NM, Gilman RH, Recarvarren S, Friedland JS
The Journal of infectious diseases 2007 Oct 1;196(7):1076-9

Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma.

Rönkkö S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2007 May;245(5):697-704

Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma.

Seo YS, Park JJ, Kim JH, Kim JY, Yeon JE, Kim JS, Byun KS, Bak YT
Digestive diseases and sciences 2007 Mar;52(3):753-9

Study of matrix metalloproteinases and their inhibitors in breast cancer.

Vizoso FJ, González LO, Corte MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL
British journal of cancer 2007 Mar 26;96(6):903-11

Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy.

Unsal Kilic D, Uner A, Akyurek N, Erpolat P, Dursun A, Pak Y
International journal of radiation oncology, biology, physics 2007 Jan 1;67(1):196-203

Modulation of extracellular matrix components by metalloproteinases and their tissue inhibitors during degeneration and regeneration of rat sural nerve.

Gantus MA, Nasciutti LE, Cruz CM, Persechini PM, Martinez AM
Brain research 2006 Nov 29;1122(1):36-46

In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.

Qian J, Niu J, Li M, Chiao PJ, Tsao MS
Cancer research 2005 Jun 15;65(12):5045-53

Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1.

Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR
Cancer research 2005 Feb 1;65(3):898-906

Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation.

Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD
Oncogene 2004 Dec 9;23(57):9212-9

Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer.

Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Aug 15;22(16):3218-29

Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway.

Liu XW, Bernardo MM, Fridman R, Kim HR
The Journal of biological chemistry 2003 Oct 10;278(41):40364-72

Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha-dependent monocyte networks.

Price NM, Gilman RH, Uddin J, Recavarren S, Friedland JS
Journal of immunology (Baltimore, Md. : 1950) 2003 Nov 15;171(10):5579-86

Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha-dependent monocyte networks.

Price NM, Gilman RH, Uddin J, Recavarren S, Friedland JS
Journal of immunology (Baltimore, Md. : 1950) 2003 Nov 15;171(10):5579-86

Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.

Zhang S, Li L, Lin JY, Lin H
World journal of gastroenterology 2003 May;9(5):899-904

Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.

Zhang S, Li L, Lin JY, Lin H
World journal of gastroenterology 2003 May;9(5):899-904

The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes.

Jo H, Park JS, Kim EM, Jung MY, Lee SH, Seong SC, Park SC, Kim HJ, Lee MC
Osteoarthritis and cartilage 2003 Aug;11(8):585-94

The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes.

Jo H, Park JS, Kim EM, Jung MY, Lee SH, Seong SC, Park SC, Kim HJ, Lee MC
Osteoarthritis and cartilage 2003 Aug;11(8):585-94

Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations.

Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, Barbaro NM, Higashida RT, Dowd CF, Halbach VV, Young WL, University of California, San Francisco BAVM Study Group
Stroke 2003 Apr;34(4):925-31

Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease.

Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH
Arteriosclerosis, thrombosis, and vascular biology 2003 Apr 1;23(4):576-81

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of TIMP-1 was performed using 70% confluent log phase MDA-MB-231 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with TIMP-1 (102D1) Mouse Monoclonal Antibody (Product # MS608PABX) at 1:250 dilution in0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry analysis of TIMP-1 (102D1) showing staining in the cytoplasm of paraffin-embedded human prostate tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a TIMP-1 Antibody (102D1) Mouse Monoclonal Antibody (Product # MS608PABX) diluted in 3% BSA-PBS at a dilution of 1:100 for 1 hour at 37°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of TIMP-1 was done on MDA-MB-231 cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with TIMP-1 Mouse Monoclonal Antibody (MS608PABX, red histogram) or with mouse isotype control (pink histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Rabbit Anti-Mouse Secondary Antibody (A11059) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10, 000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Left: examples of TMAs with immunostaining for each protein. 200 x Right: ( A ) immunohistochemical staining of MMP2 in epithelial cells, ( B ) TIMP3 in epithelial cells and fibroblastic cells, ( C ) TIMP3 in inflammatory mononuclear cells, and ( D ) TIMP2 in epithelial cells, fibroblast and inflammatory mononuclear cells. 400 x .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Left: examples of tissue with immunostaining for the more significant proteins in patients with tumours belong to poor prognostic group (cluster 2 group: A , B and C ) and better prognostic group (cluster 1 group: D , E and F ; magnification x 400). ( A ) Immunohistochemical staining of matrix metalloproteinase (MMP)-11 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. ( B ) Immunohistochemical staining of MMP-9 in inflammatory mononuclear cells, tumour cells and fibroblastic cell negatives. ( C ) Immunohistochemical staining of tissular inhibitors of metalloproteinase (TIMP)-1 in inflammatory mononuclear cells and in fibroblastic cells, tumour cell negatives. ( D ) No immunohistochemical staining of MMP-9 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. ( E ) Immunohistochemical staining of MMP-11 in tumour cells, inflammatory mononuclear cells and fibroblastic cell negatives. ( F ) Immunohistochemical staining of TIMP-1 in fibroblastic cells, inflammatory mononuclear cells and tumour cell negatives. In all cases, inflammatory mononuclear cells are indicated with small arrows, and fibroblastic cells with large arrows.